Cargando…

Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions

Therapy of recurrent glioblastoma (GBM) is challenging due to lack of standard treatment. We investigated physicians’ treatment choice at recurrence and prognostic and predictive factors for survival in GBM patients from Norway’s two largest regional hospitals. Clinicopathological data from n = 467...

Descripción completa

Detalles Bibliográficos
Autores principales: Blakstad, Hanne, Brekke, Jorunn, Rahman, Mohummad Aminur, Arnesen, Victoria Smith, Miletic, Hrvoje, Brandal, Petter, Lie, Stein Atle, Chekenya, Martha, Goplen, Dorota
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894455/
https://www.ncbi.nlm.nih.gov/pubmed/36730349
http://dx.doi.org/10.1371/journal.pone.0281166
_version_ 1784881743876063232
author Blakstad, Hanne
Brekke, Jorunn
Rahman, Mohummad Aminur
Arnesen, Victoria Smith
Miletic, Hrvoje
Brandal, Petter
Lie, Stein Atle
Chekenya, Martha
Goplen, Dorota
author_facet Blakstad, Hanne
Brekke, Jorunn
Rahman, Mohummad Aminur
Arnesen, Victoria Smith
Miletic, Hrvoje
Brandal, Petter
Lie, Stein Atle
Chekenya, Martha
Goplen, Dorota
author_sort Blakstad, Hanne
collection PubMed
description Therapy of recurrent glioblastoma (GBM) is challenging due to lack of standard treatment. We investigated physicians’ treatment choice at recurrence and prognostic and predictive factors for survival in GBM patients from Norway’s two largest regional hospitals. Clinicopathological data from n = 467 patients treated at Haukeland and Oslo university hospitals from January 2015 to December 2017 was collected. Data included tumour location, promoter methylation of O(6) methylguanine-DNA methyltransferase (MGMT) and mutation of isocitrate dehydrogenase (IDH), patient age, sex, extent of resection at primary diagnosis and treatment at successive tumour recurrences. Cox-proportional hazards regression adjusting for multiple risk factors was used. Median overall survival (OS) was 12.1 months and 21.4% and 6.8% of patients were alive at 2 and 5 years, respectively. Median progression-free survival was 8.1 months. Treatment at recurrence varied but was not associated with difference in overall survival (OS) (p = 0.201). Age, MGMT hypermethylation, tumour location and extent of resection were independent prognostic factors. Patients who received 60 Gray radiotherapy with concomitant and adjuvant temozolomide at primary diagnosis had 16.1 months median OS and 9.3% were alive at 5 years. Patients eligible for gamma knife/stereotactic radiosurgery alone or combined with chemotherapy at first recurrence had superior survival compared to chemotherapy alone (p<0.001). At second recurrence, combination chemotherapy with or without bevacizumab were both superior to no treatment. Treatment at recurrence differed between the institutions but there was no difference in median OS, indicating that it is the disease biology that dictates patient outcome.
format Online
Article
Text
id pubmed-9894455
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-98944552023-02-03 Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions Blakstad, Hanne Brekke, Jorunn Rahman, Mohummad Aminur Arnesen, Victoria Smith Miletic, Hrvoje Brandal, Petter Lie, Stein Atle Chekenya, Martha Goplen, Dorota PLoS One Research Article Therapy of recurrent glioblastoma (GBM) is challenging due to lack of standard treatment. We investigated physicians’ treatment choice at recurrence and prognostic and predictive factors for survival in GBM patients from Norway’s two largest regional hospitals. Clinicopathological data from n = 467 patients treated at Haukeland and Oslo university hospitals from January 2015 to December 2017 was collected. Data included tumour location, promoter methylation of O(6) methylguanine-DNA methyltransferase (MGMT) and mutation of isocitrate dehydrogenase (IDH), patient age, sex, extent of resection at primary diagnosis and treatment at successive tumour recurrences. Cox-proportional hazards regression adjusting for multiple risk factors was used. Median overall survival (OS) was 12.1 months and 21.4% and 6.8% of patients were alive at 2 and 5 years, respectively. Median progression-free survival was 8.1 months. Treatment at recurrence varied but was not associated with difference in overall survival (OS) (p = 0.201). Age, MGMT hypermethylation, tumour location and extent of resection were independent prognostic factors. Patients who received 60 Gray radiotherapy with concomitant and adjuvant temozolomide at primary diagnosis had 16.1 months median OS and 9.3% were alive at 5 years. Patients eligible for gamma knife/stereotactic radiosurgery alone or combined with chemotherapy at first recurrence had superior survival compared to chemotherapy alone (p<0.001). At second recurrence, combination chemotherapy with or without bevacizumab were both superior to no treatment. Treatment at recurrence differed between the institutions but there was no difference in median OS, indicating that it is the disease biology that dictates patient outcome. Public Library of Science 2023-02-02 /pmc/articles/PMC9894455/ /pubmed/36730349 http://dx.doi.org/10.1371/journal.pone.0281166 Text en © 2023 Blakstad et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Blakstad, Hanne
Brekke, Jorunn
Rahman, Mohummad Aminur
Arnesen, Victoria Smith
Miletic, Hrvoje
Brandal, Petter
Lie, Stein Atle
Chekenya, Martha
Goplen, Dorota
Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions
title Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions
title_full Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions
title_fullStr Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions
title_full_unstemmed Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions
title_short Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions
title_sort survival in a consecutive series of 467 glioblastoma patients: association with prognostic factors and treatment at recurrence at two independent institutions
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894455/
https://www.ncbi.nlm.nih.gov/pubmed/36730349
http://dx.doi.org/10.1371/journal.pone.0281166
work_keys_str_mv AT blakstadhanne survivalinaconsecutiveseriesof467glioblastomapatientsassociationwithprognosticfactorsandtreatmentatrecurrenceattwoindependentinstitutions
AT brekkejorunn survivalinaconsecutiveseriesof467glioblastomapatientsassociationwithprognosticfactorsandtreatmentatrecurrenceattwoindependentinstitutions
AT rahmanmohummadaminur survivalinaconsecutiveseriesof467glioblastomapatientsassociationwithprognosticfactorsandtreatmentatrecurrenceattwoindependentinstitutions
AT arnesenvictoriasmith survivalinaconsecutiveseriesof467glioblastomapatientsassociationwithprognosticfactorsandtreatmentatrecurrenceattwoindependentinstitutions
AT miletichrvoje survivalinaconsecutiveseriesof467glioblastomapatientsassociationwithprognosticfactorsandtreatmentatrecurrenceattwoindependentinstitutions
AT brandalpetter survivalinaconsecutiveseriesof467glioblastomapatientsassociationwithprognosticfactorsandtreatmentatrecurrenceattwoindependentinstitutions
AT liesteinatle survivalinaconsecutiveseriesof467glioblastomapatientsassociationwithprognosticfactorsandtreatmentatrecurrenceattwoindependentinstitutions
AT chekenyamartha survivalinaconsecutiveseriesof467glioblastomapatientsassociationwithprognosticfactorsandtreatmentatrecurrenceattwoindependentinstitutions
AT goplendorota survivalinaconsecutiveseriesof467glioblastomapatientsassociationwithprognosticfactorsandtreatmentatrecurrenceattwoindependentinstitutions